<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00598507</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-14965</org_study_id>
    <secondary_id>ZK219477</secondary_id>
    <secondary_id>108.0701</secondary_id>
    <nct_id>NCT00598507</nct_id>
  </id_info>
  <brief_title>Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma</brief_title>
  <official_title>Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out how effective an investigational drug named ZK-Epo&#xD;
      is against melanoma. Although ZK-Epo has been studied in the treatment of cancer, it is not&#xD;
      approved for use in treating melanoma. This research is being done because currently there&#xD;
      are only a limited number of treatment options for patients who have melanoma that has spread&#xD;
      to distant organs.&#xD;
&#xD;
      We expect each patient to be in this study for at least 2 cycles. One cycle lasts for 21&#xD;
      days. If their tumor does not grow after 2 cycles and they do not have any major&#xD;
      side-effects, they may receive up to 6 cycles of ZK-Epo.&#xD;
&#xD;
      If after they have received 6 cycles of ZK-Epo and their doctor determines that the tumor is&#xD;
      continuing to shrink, they will continue treatment with ZK-Epo. The number of treatments the&#xD;
      patient receives after 6 cycles will depend upon when their doctor feels there has been&#xD;
      maximum tumor response (tumor shrinkage). Two treatments will be given beyond what their&#xD;
      doctor considers the point of maximum shrinkage. We estimate that they will spend anywhere&#xD;
      from 1 1/2 months to 5 months taking part in this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each Cycle is a 21 day period. On the first day of each cycle each patient will receive the&#xD;
      study drug, ZK-Epo, through an IV infusion over a 3 hour period. Patients will receive the&#xD;
      study drug only once every 21 day period.&#xD;
&#xD;
      At the start of each cycle patients will have the following tests:&#xD;
&#xD;
        -  Patients will be asked questions about their medical history and health and undergo a&#xD;
           complete physical exam.&#xD;
&#xD;
        -  Blood tests will be done to check blood cell count and organ functions (about 1&#xD;
           tablespoon of blood will be taken).&#xD;
&#xD;
        -  Performance status tests (will determine patient's ability to perform everyday&#xD;
           functions).&#xD;
&#xD;
        -  A nurse or doctor will ask patients how they are feeling and about any side effects that&#xD;
           patients may be having.&#xD;
&#xD;
        -  Pre Study Visit: Blood test called lactate dehydrogenase (LDH) to check organ function.&#xD;
           Prothrombin time (PT) and an a partial thromboplastin time (PTT) to see if the patient's&#xD;
           blood clots normally. Electrocardiogram (EKG) (to measure the electrical function of&#xD;
           patient's heart). Pregnancy Test (IF APPLICABLE a woman of child bearing age). Optional&#xD;
           Tumor Biopsy (If indicated by patient's physician).&#xD;
&#xD;
        -  Cycle 1, Day 1: Pharmacokinetics: special blood tests to measure the drug levels, LDH&#xD;
&#xD;
        -  Cycle 1, Day 2 &amp; 8: Pharmacokinetics&#xD;
&#xD;
        -  Cycle 1, Day 15: EKG&#xD;
&#xD;
        -  Cycle 2, DAY 1: LDH&#xD;
&#xD;
        -  Cycle 3, DAY 1: LDH, PT &amp; activated partial thromboplastin time (aPTT)&#xD;
&#xD;
        -  Cycle 4, 5, &amp; 6, and all subsequent cycles, Day 1: LDH&#xD;
&#xD;
      During the first cycle only patients will also need to come for a study visit on day 8 and&#xD;
      15. During these two visits, blood tests will be done again to check blood cell count and&#xD;
      organ functions. Patients will also be asked how they are feeling and about any side effects&#xD;
      that they may be having.&#xD;
&#xD;
      Computed tomography (CT) scans or a magnetic resonance imaging (MRI) will be done after every&#xD;
      2 cycles that each patient completes on the study. These will be done to help the doctor&#xD;
      re-evaluate each patient's disease.&#xD;
&#xD;
      Patients may have some additional blood tests done if they are among the first 10 patients&#xD;
      taking part in this study. In this case they will have 9 samples of blood (each about a&#xD;
      teaspoonful) drawn from them at specifically timed intervals (at 30 minutes before the start&#xD;
      and at 30 minutes, 2 hour 55 minutes, 3 hour 10 minutes, 3 hour 30 minutes, 5 hour, 8 hour,&#xD;
      27 hour (+/- 1 hour) and 168 hour (+/- 4 hours) after the start of the ZK-Epo infusion) so&#xD;
      that we can better understand the level of this drug in the body and its metabolism in&#xD;
      people.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Objective tumor response according to Response Evaluation Criteria In Solid Tumors (RECIST). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Stable disease is measured from the start of the treatment until the criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started, including the baseline measurements. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Progression Free Survival (PFS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>PFS: the duration of time from start of treatment to time of progression or death, whichever occurs first. Progressive Disease (PD)according to modified Response Evaluation Criteria in Solid Tumors (RECIST) Criteria: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Median OS: the time (expressed in months or years) when half the patients are expected to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Attributable Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Number of participants with Grade 3 or higher adverse events, attributable to treatment with sagopilone.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Chemotherapy - ZK-EPO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZK-EPO (ZK 219477) (Sagopilone), 16 mg/m^2, was administered intravenously over 3-hours every 21 days until progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZK-EPO</intervention_name>
    <description>Participants were treated with 16 mg/m^2 of ZK-EPO (EpothiloneZK) (Sagopilone) administered as a single 3 hour intravenous infusion every 21 days. Prior to each treatment, participants were premedicated with either granisetron or ondansetron and additional anti-emetics if needed. Chemotherapy was continued until disease progression, withdrawal of consent, or for unacceptable treatment-associated toxicity.</description>
    <arm_group_label>Chemotherapy - ZK-EPO</arm_group_label>
    <other_name>EpothiloneZK</other_name>
    <other_name>ZK 219477</other_name>
    <other_name>Sagopilone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed Malignant Melanoma.&#xD;
&#xD;
          -  Unresectable Stage III or Stage IV disease.&#xD;
&#xD;
          -  At least 1 measurable lesion.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2.&#xD;
&#xD;
          -  Adequate function of major organs and systems as measured by the following criteria:&#xD;
&#xD;
        Bone Marrow:&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  White blood count (WBC) ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin within 1.5 times normal limit&#xD;
&#xD;
          -  aspartate transaminase (AST)/Alanine aminotransferase (ALT) ≤ 5 times the upper limit&#xD;
             of normal (ULN)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine ≤ 2 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association (NYHA) class III or IV Congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No arrhythmia needing continuous treatment&#xD;
&#xD;
        Nervous system:&#xD;
&#xD;
          -  No Grade ≥ 2 peripheral neuropathy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than 2 previous chemotherapy regimens.&#xD;
&#xD;
          -  Any prior treatment with Epothilones, Epothilone analogues, taxanes, or vinca&#xD;
             alkaloids.&#xD;
&#xD;
          -  Any progressive central nervous system (CNS) metastatic disease. Patients with CNS&#xD;
             metastases may be allowed if stable for 8 weeks or more and patient is neurologically&#xD;
             intact and off of steroids. The stability must be documented by MRI/CT over a period&#xD;
             of 8 weeks or greater.&#xD;
&#xD;
          -  Any radiotherapy, chemotherapy, or immunotherapy within 3 weeks prior to first dose of&#xD;
             ZK-Epo. If patients were previously on temozolomide with extended dose schedule, they&#xD;
             must be off 1 week prior to the first dose of ZK-Epo.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald DeConti, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2008</study_first_posted>
  <results_first_submitted>September 12, 2013</results_first_submitted>
  <results_first_submitted_qc>September 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 15, 2013</results_first_posted>
  <last_update_submitted>November 15, 2013</last_update_submitted>
  <last_update_submitted_qc>November 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ZK-EPO</keyword>
  <keyword>ZK219477</keyword>
  <keyword>EpothiloneZK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sagopilone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Accrual began in May 2007 at Moffitt Cancer Center and was completed in October 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Chemotherapy - ZK-EPO</title>
          <description>ZK-EPO (ZK 219477) (Sagopilone), 16 mg/m^2, was administered intravenously over 3-hours every 21 days until progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants treated with at least one dose of sagopilone.</population>
      <group_list>
        <group group_id="B1">
          <title>Chemotherapy - ZK-EPO</title>
          <description>ZK-EPO (ZK 219477) (Sagopilone), 16 mg/m^2, was administered intravenously over 3-hours every 21 days until progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.7" spread="1.7" lower_limit="37" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate (RR)</title>
        <description>Objective tumor response according to Response Evaluation Criteria In Solid Tumors (RECIST). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Stable disease is measured from the start of the treatment until the criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started, including the baseline measurements. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).</description>
        <time_frame>Up to 5 years</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy - ZK-EPO</title>
            <description>ZK-EPO (ZK 219477) (Sagopilone), 16 mg/m^2, was administered intravenously over 3-hours every 21 days until progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (RR)</title>
          <description>Objective tumor response according to Response Evaluation Criteria In Solid Tumors (RECIST). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Stable disease is measured from the start of the treatment until the criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started, including the baseline measurements. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).</description>
          <population>All participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Confirmed Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconfirmed Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease for at Least 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression Free Survival (PFS)</title>
        <description>PFS: the duration of time from start of treatment to time of progression or death, whichever occurs first. Progressive Disease (PD)according to modified Response Evaluation Criteria in Solid Tumors (RECIST) Criteria: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).</description>
        <time_frame>Up to 5 years</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy - ZK-EPO</title>
            <description>ZK-EPO (ZK 219477) (Sagopilone), 16 mg/m^2, was administered intravenously over 3-hours every 21 days until progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression Free Survival (PFS)</title>
          <description>PFS: the duration of time from start of treatment to time of progression or death, whichever occurs first. Progressive Disease (PD)according to modified Response Evaluation Criteria in Solid Tumors (RECIST) Criteria: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).</description>
          <population>All participants</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="6.4" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival (OS)</title>
        <description>Median OS: the time (expressed in months or years) when half the patients are expected to be alive.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy - ZK-EPO</title>
            <description>ZK-EPO (ZK 219477) (Sagopilone), 16 mg/m^2, was administered intravenously over 3-hours every 21 days until progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival (OS)</title>
          <description>Median OS: the time (expressed in months or years) when half the patients are expected to be alive.</description>
          <population>All participants</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="14.9" upper_limit="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Attributable Serious Adverse Events (SAEs)</title>
        <description>Number of participants with Grade 3 or higher adverse events, attributable to treatment with sagopilone.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy - ZK-EPO</title>
            <description>ZK-EPO (ZK 219477) (Sagopilone), 16 mg/m^2, was administered intravenously over 3-hours every 21 days until progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Attributable Serious Adverse Events (SAEs)</title>
          <description>Number of participants with Grade 3 or higher adverse events, attributable to treatment with sagopilone.</description>
          <population>All participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 5 years</time_frame>
      <desc>Participants treated with at least one dose of sagopilone.</desc>
      <group_list>
        <group group_id="E1">
          <title>Chemotherapy - ZK-EPO</title>
          <description>ZK-EPO (ZK 219477) (Sagopilone), 16 mg/m^2, was administered intravenously over 3-hours every 21 days until progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC V3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term - Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Fever in the absence of neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine - high</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC V3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin - low</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC) - low</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC) - low</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Platelets - low</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain - Extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain - Muscle</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain - Bone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain - Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Lymphatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase) - high</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase) - high</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ronald DeConti, M.D., Principal Investigator</name_or_title>
      <organization>H. Lee Moffitt Cancer Center and Research Institute</organization>
      <phone>813-745-8466</phone>
      <email>ronald.deconti@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

